Physician profile
Paul Deneault
NPI 1346276177
$8,829.08
in general payments reported to CMS, 2019-2025
41 companies · $2,602 in 2025
The $2,602 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,181 · 2020: $1,095 · 2021: $1,481 · 2022: $892 · 2023: $536 · 2024: $1,043 · 2025: $2,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Travel and Lodging: $1,191 · Consulting Fee: $600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.14 |
| Travel and Lodging | $1,191.42 |
| Consulting Fee | $600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,255.17 | 2019-2025 | Rinvoq, Linzess, Humira |
| Olympus Medical Systems Corporation | $1,000.00 | 2025 | Gastrointestinal Videoscope |
| Boston Scientific Corporation | $933.91 | 2020-2025 | Spyglass, Spyglass |
| Takeda Pharmaceuticals U.S.A., INC. | $630.06 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $551.82 | 2019-2025 | |
| Janssen Biotech, INC. | $386.34 | 2020-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $369.87 | 2019-2025 | |
| Celgene Corporation | $243.39 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.41 | 2019-2024 | Trulance, Xifaxan |
| Allergan, INC. | $217.50 | 2020 | |
| Redhill Biopharma INC. | $151.05 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $146.49 | 2024 | Dupixent |
| Covidien Lp | $143.14 | 2019 | |
| Genzyme Corporation | $120.29 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.53 | 2021 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Deneault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.